MTHFR C677T polymorphism as a risk factor for vascular calcification in chronic hemodialysis patients

Journal of Korean Medical Science

Volumn 26, Issue 3, 2011, Pages 461-465

  Lee, So Young ^a   Kim, Hoe young ^a   Park, Kyung Mi ^a   Lee, Stephen Yon Gu ^a   Hong, Seong Geun ^a   Kim, Hyung Jong ^a   Yang, Dong Ho ^a  

^a CHA University   (South Korea)

Author keywords

Homocysteine; Methylenetetrahydrofolate reductase (MTHFR); Renal dialysis; Vascular calcification

Indexed keywords

METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

AGED; ARTICLE; CALCINOSIS; CHRONIC KIDNEY FAILURE; GENETIC PREDISPOSITION; GENETICS; HUMAN; MIDDLE AGED; RENAL REPLACEMENT THERAPY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULAR DISEASE;

AGED; CALCINOSIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY FAILURE, CHRONIC; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RENAL DIALYSIS; RISK FACTORS; VASCULAR DISEASES;

EID: 79953749112     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2011.26.3.461     Document Type: Article

References (20)

1. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996; 27: 394-401.
2. London GM, Marchais SJ, Guérin AP, Métivier F. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens 2005; 14: 525-31.
3. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-3.
4. Spark JI, Laws P, Fitridge R. The incidence of hyperhomocysteinaemia in vascular patients. Eur J Vasc Endovasc Surg 2003; 26: 558-61.
5. Wald DS, Wald NJ, Morris JK, Law M. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ 2006; 333: 1114-7.
6. Khandanpour N, Willis G, Meyer FJ, Armon MP, Loke YK, Wright AJ, Finglas PM, Jennings BA. Peripheral arterial disease and methylenetetrahydrofolate reductase (MTHFR) C677T mutations: a case-control study and meta-analysis. J Vasc Surg 2009; 49: 711-8.
7. Adragão T, Pires A, Birne R, Curto JD, Lucas C, Gonçalves M, Negrão AP. A plain X-ray vascular calcification score is associated with arterial stiffness and mortality in dialysis patients. Nephrol Dial Transplant 2009; 24: 997-1002.
8. Cozzolino M, Biondi ML, Galassi A, Cusi D, Brancaccio D, Gallieni M. Vascular calcification and cardiovascular outcome in dialysis patients: the role of gene polymorphisms. Blood Purif 2010; 29: 347-51.
9. Jamison RL, Shih MC, Humphries DE, Guarino PD, Kaufman JS, Goldfarb DS, Warren SR, Gaziano JM, Lavori P.; Veterans Affairs Site Investigators. Effect of the MTHFR C677T and A1298C polymorphisms on survival in patients with advanced CKD and ESRD: a prospective study. Am J Kidney Dis 2009; 53: 779-89.
10. Friedman AN, Bostom AG, Selhub J, Levey AS, Rosenberg IH. The kidney and homocysteine metabolism. J Am Soc Nephrol 2001; 12: 2181-9.
11. Ebbing M, Bleie Ø, Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE, Refsum H, Pedersen EK, Nygård O. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA 2008; 300: 795-804.
12. Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM.; Veterans Affairs Site Investigators. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007; 298: 1163-70.
13. Antoniades C, Shirodaria C, Leeson P, Baarholm OA, Van-Assche T, Cunnington C, Pillai R, Ratnatunga C, Tousoulis D, Stefanadis C, Refsum H, Channon KM. MTHFR 677 C>T Polymorphism reveals functional importance for 5-methyltetrahydrofolate, not homocysteine, in regulation of vascular redox state and endothelial function in human atherosclerosis. Circulation 2009; 119: 2507-15.
14. Adragao T, Pires A, Lucas C, Birne R, Magalhaes L, Gonçalves M, Negrao AP. A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1480-8.
15. Annuk M, Zilmer M, Lind L, Linde T, Fellström B. Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol 2001; 12: 2747-52.
16. Agabiti-Rosei E, Heagerty AM, Rizzoni D. Effects of antihypertensive treatment on small artery remodelling. J Hypertens 2009; 27: 1107-14.
17. Levy D, Hwang SJ, Kayalar A, Benjamin EJ, Vasan RS, Parise H, Larson MG, Wang TJ, Selhub J, Jacques PF, Vita JA, Keyes MJ, Mitchell GF. Associations of plasma natriuretic peptide, adrenomedullin, and homocysteine levels with alterations in arterial stiffness: the Framingham Heart Study. Circulation 2007; 115: 3079-85.
18. Ichihara A, Hayashi M, Kaneshiro Y, Takemitsu T, Homma K, Kanno Y, Yoshizawa M, Furukawa T, Takenaka T, Saruta T. Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. Am J Kidney Dis 2005; 45: 866-74.
19. Ferrier KE, Muhlmann MH, Baguet JP, Cameron JD, Jennings GL, Dart AM, Kingwell BA. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39: 1020-5.
20. Mahmud A, Feely J. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens 2008; 21: 663-7.